Showing 601-620 of 746 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Psychostimulants for depression
Cochrane Systematic Reviews, 4-Nov-2008
Depression is common, disabling, costly and under-treated. There are problems in the current first-line drug treatment, antidepressants, for moderate or severe depression. There is a body of research that has evaluated the effect of psychostimulants (PS)
- Psychotropic analgesic nitrous oxide for alcoholic withdrawal states
Cochrane Systematic Reviews, 12-Aug-2008
Alcoholism is a global problem with 5-10% of the world's population demonstrating alcohol-related diseases. One of the most severe consequences of alcohol dependence is the withdrawal syndrome, for which benzodiazepines are the most popular current treatm
- Quetiapine for schizophrenia
Cochrane Systematic Reviews, 19-Apr-2004
Quetiapine is an atypical antipsychotic with, theoretically, a low propensity for movement disorder adverse effects. It is used for the treatment of schizophrenia and other psychoses.
- Quetiapine versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 18-Nov-2013
In many countries, second-generation ('atypical') antipsychotic drugs have become the first-line drug treatment for people with schizophrenia. It is not clear how the effects of the various second-generation antipsychotic drugs differ.
- Quinolones for uncomplicated acute cystitis in women
Cochrane Systematic Reviews, 19-Jul-2006
Uncomplicated acute cystitis is one of the most common bacterial infections in adults. The percentage of women who have at least one episode of acute cystitis is estimated to be between 40% to 50%. Quinolones are recommended for acute cystitis in regions
- Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Cochrane Systematic Reviews, 14-Mar-2012
Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia and inhibitory allo-antibodies and for prophylaxis and treatment of patients with congenital factor VII deficiency. It is also used for off-license indications to prevent bl
- Recompression and adjunctive therapy for decompression illness
Cochrane Systematic Reviews, 16-May-2012
Decompression illness (DCI) is due to bubble formation in the blood or tissues following the breathing of compressed gas. Clinically, DCI may range from a trivial illness to loss of consciousness, death or paralysis. Recompression is the universally accep
- Rectal analgesia for pain from perineal trauma following childbirth
Cochrane Systematic Reviews, 29-Oct-2008
Perineal pain from a tear and/or surgical cut (episiotomy) is a common problem following vaginal birth. Strategies to reduce perineal trauma and the appropriate repair of any perineal damage sustained are important for avoiding and alleviating pain. Where
- Reduced or modified dietary fat for preventing cardiovascular disease
Cochrane Systematic Reviews, 21-Nov-2017
Reduction and modification of dietary fats have differing effects on cardiovascular risk factors (such as serum cholesterol), but their effects on important health outcomes are less clear.
- Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
Cochrane Systematic Reviews, 14-Apr-2021
Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest tightness, and cough. Treatment with inhaled steroids and bronchodilators can result in good control of symptoms, prevention of further morbidi
- Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma
Cochrane Systematic Reviews, 22-Jul-2002
Selective beta-adrenergic agonists for use in asthma are: short acting (2 to 6 hours) and long acting (> 12 hours). There has been little controversy about using short acting beta-agonists intermittently, but long acting beta-agonists are used regularly,
- Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes
Cochrane Systematic Reviews, 5-Jul-2015
It has been unclear whether repeat dose(s) of prenatal corticosteroids are beneficial.
- Retinoids for preventing the progression of cervical intra‐epithelial neoplasia
Cochrane Systematic Reviews, 6-Jun-2013
Invasive cervical carcinoma is preceded by a precancerous phase, cervical intra-epithelial neoplasia (CIN), which can be detected on cervical smears and confirmed by colposcopy and biopsy. Moderate and severe cases of intra-epithelial neoplasia (CIN2 and
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
Cochrane Systematic Reviews, 24-May-2010
Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk. Risedronate belongs to the bisphosphonate class of drugs which act to inhibit bone resorption by interfering with the activity of osteoclasts.
- Risperidone alone or in combination for acute mania
Cochrane Systematic Reviews, 25-Jan-2006
Risperidone, an atypical antipsychotic, is used to treat mania both alone and in combination with other medicines.
- Risperidone versus other atypical antipsychotic medication for schizophrenia
Cochrane Systematic Reviews, 20-Sep-2016
Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional a
- Risperidone versus typical antipsychotic medication for schizophrenia
Cochrane Systematic Reviews, 22-Apr-2003
Risperidone is one of the 'new generation' antipsychotics. As well as its reputed tendency to cause fewer movement disorders than the older drugs such as chlorpromazine and haloperidol, it is claimed that risperidone may improve negative symptoms.
- Rizatriptan for acute migraine
Cochrane Systematic Reviews, 10-Jun-2019
There are a number of different drug treatments for acute migraine, including currently four triptans, with several more likely to become available in the future. There is a need for evidence-based information to help determine the balance of benefit and
- Rofecoxib for rheumatoid arthritis
Cochrane Systematic Reviews, 24-Jan-2005
Editor's note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke. Further information i
- Rosiglitazone for type 2 diabetes mellitus
Cochrane Systematic Reviews, 18-Jul-2007
Diabetes has long been recognised as a strong, independent risk factor for cardiovascular disease, a problem which accounts for approximately 70% of all mortality in people with diabetes. Prospective studies show that compared to their non-diabetic counte
